1.Several quarters passed since Kerx Pharmaceuticals (KERX) reported production issues that would delay the manufacture of Auryxia for the treatment of renal diseases. Since then, the stock, for which this group alerted members, rebounded. Kerx closed at a yearly high. Earnings growth will reach positive territory in 2020.Source: simplyWallStOn 05/04/2017, Kerx reported revenue of $11.8 million. It forecast Auryxia sales of between $56 - $60 million for the full year, 2017. The CEO said: "In the first quarter, prescription growth continued across the dialysis patient population, with strong demand from both new patients and patients who have switched from another phosphate binder."Kerx ended the quarter (as at Mar 31) with $90.9M in cash. It burnt through $20.9M during the first quarter. 2.Synergy Pharmaceuticals (SGYP) reported positive clinical numbers this past weekend. Expect scripts growing as adoption for Trulance takes hold. EPS growth is years away but SGYP could get buyout offers as sales grow.Source: simplyWallStPer Synergy, "TRULANCE is a once-daily tablet approved by the Food and Drug Administration (FDA) for the treatment of adults with chronic idiopathic constipation (CIC) and is currently being evaluated for the treatment of adults with IBS-C. The recommended dosage of TRULANCE for CIC is 3 mg taken orally, once daily, with or without food at any time of the day."The presentation schedule is as follows:- Tuesday, May 9 – 10:45 a.m.-11:00 a.m. CT- Sunday, May 7 – 12:00 p.m.-2:00 p.m. CT (poster presentation) 3.Immunomedics (IMMU) announced a private placement offering that will raise $125 million for the company. It also terminated its agreement with SGEN (Seattle Genetics). IMMU now has full rights to IMMU-132, a drug candidate that treats metastatic triple-negative breast cancer (mTNBC).